Related Experiment Videos
DAT polymorphism and diverse clinical manifestations in methamphetamine abusers.
Hsing-Cheng Liu1, Shih-Ku Lin, Shih-Kai Liu
1Department of Addiction Science and Molecular Psychiatry Laboratory, Taipei City Psychiatric Center, Taipei, Taiwan.
Psychiatric Genetics
|April 20, 2004
Summary
This study investigated the dopamine transporter (DAT) gene polymorphism in methamphetamine (MAP) abusers. No significant association was found between the DAT polymorphism and clinical variations in MAP abusers.
Area of Science:
- Neuroscience
- Genetics
- Psychiatry
Background:
- Methamphetamine (MAP) abuse leads to variable clinical outcomes.
- The dopamine transporter (DAT) is crucial for regulating dopamine levels and is implicated in MAP's neurotoxicity.
- Genetic variations in DAT may influence individual responses to MAP.
Purpose of the Study:
- To examine the association between a specific DAT gene polymorphism and diverse clinical outcomes in methamphetamine abusers.
- To investigate the role of the 40 base pair variable number tandem repeat polymorphism in the 3'-untranslated region of DAT.
Main Methods:
- Recruited 146 MAP abusers classified into dependence, psychosis, and chronic psychosis groups.
- Included schizophrenia patients (n=79) and healthy controls (n=72) for comparison.
- Analyzed the allelic frequencies of the 40 base pair variable number tandem repeat polymorphism in the 3'-untranslated region of the DAT gene.
Main Results:
- No statistically significant associations were found between DAT polymorphism genotype/allele frequencies and the clinical outcomes of MAP abusers.
- Allelic frequencies for DAT repeats 11, 10, and 9 were analyzed across all groups.
Conclusions:
- The investigated DAT gene polymorphism does not appear to be significantly associated with clinical variations in methamphetamine abusers.
- The biological relevance of this specific DAT polymorphism in the context of MAP abuse was not demonstrated in this study.